C. Purpose of this Guidance, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA

  • To outline the practical arrangements for notification.
  • To provide advice on what should and what should not be classified as a “serious breach” and what must be reported.
  • To outline possible actions that may be taken by the MHRA in response to notifications of serious breaches.

Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency

Clinical Research News

Radiological Society of North America Study: Genicular Artery Embolization Reduces Knee Osteoarthritis Pain for 12 Months
GLP-1 and Fertility: Why Weight Loss Drugs Are Being Discussed in Reproductive Medicine
High Lp(a): New Trial to Test Drug Combination Against Hereditary Heart Risk
Weight Loss Drugs Linked to Lower Risk of Certain Cancers: What the New Data Shows
After Stroke and Brain Hemorrhage: New Trial to Test When Anticoagulants Are Needed
First AI-Designed Vaccine Completes Human Trials
Blood in Urine and Suspected Tumor: New Urine Test to be Compared Against Cystoscopy and Biopsy

Upcoming Clinical Trials

Clinical Research Jobs

More jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Subscribe